Annexin Pharmaceuticals: ANXV Well Tolerated in Phase I study - Redeye

Annexin Pharmaceuticals announced yesterday positive results from its anticipated phase I study, a milestone for the company and its lead candidate ANXV. The market reaction was modest and we reiterate our stance that significant progress in the company largely has gone unnoticed. We raise our base case to SEK 4.5 (4) following the positive data.

Länk till analysen i sin helhet: https://www.redeye.se/research/820772/annexin-pharmaceuticals-anxv-well-tolerated-in-phase-i-study?utm_source=finwire&utm_medium=RSS